Seattle Genetics, Inc.
(NASDAQ : SGEN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.32%293.161.4%$592.40m
AMGNAmgen, Inc.
0.46%235.081.3%$505.49m
GILDGilead Sciences, Inc.
0.66%67.591.0%$365.29m
REGNRegeneron Pharmaceuticals, Inc.
0.11%373.952.6%$302.86m
VRTXVertex Pharmaceuticals, Inc.
0.05%220.121.9%$273.16m
CLVSClovis Oncology, Inc.
13.14%13.2614.7%$235.12m
ILMNIllumina, Inc.
0.21%321.253.5%$232.38m
ARWRArrowhead Pharmaceuticals, Inc.
-1.46%67.2311.4%$204.80m
ALXNAlexion Pharmaceuticals, Inc.
1.95%111.632.0%$198.83m
EXASEXACT Sciences Corp.
0.07%85.2324.0%$163.44m
AAgilent Technologies, Inc.
1.09%84.331.6%$160.80m
GBTGlobal Blood Therapeutics, Inc.
-1.98%76.906.0%$139.28m
BLUEbluebird bio, Inc.
-2.40%84.8814.2%$136.44m
BOLDAudentes Therapeutics, Inc.
-0.09%59.391.4%$134.15m
SGENSeattle Genetics, Inc.
0.97%112.426.1%$129.79m

Company Profile

Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.